Full-Time

Senior Manager

Agile Transformation, Commercial Ops

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Project & Program Management
Required Skills
Agile
Product Management
Risk Management
SCRUM

Get referred to Amgen

See people who can refer or advise you

Requirements
  • 12–17 years of experience managing, mentoring, and developing Scrum Masters, Release Train Engineers, Product Analysts, or Product Managers.
  • Direct hands-on experience with Agile and product software delivery in roles such as Scrum Master, Release Train Engineer, Product Owner or Product Manager, Agile Coach, or SAFe Practice Consultant.
  • Proven experience leading Agile transformations that delivered measurable improvements in delivery performance, team maturity, stakeholder alignment, or business outcomes.
  • Strong understanding of SAFe principles, Agile delivery practices, Lean-Agile mindset, Agile governance, product management, and continuous improvement methods.
  • Experience facilitating Agile training, workshops, coaching sessions, transformation planning, and outcome-based improvement initiatives.
  • Experience collaborating with global and geographically dispersed teams.
  • Ability to connect Agile practices with business objectives, product outcomes, stakeholder value, and enterprise priorities.
  • Ability to foster a culture of collaboration, innovation, accountability, continuous improvement, and measurable value delivery.
Responsibilities
  • Lead Agile transformation across CCFT with a clear focus on improving business outcomes, delivery predictability, product value, stakeholder satisfaction, operational efficiency, and time-to-market.
  • Assess Agile maturity across teams and Agile Release Trains to identify opportunities that improve execution, flow, quality, transparency, and value realization.
  • Develop and implement Agile maturity accelerators that help teams move beyond process adoption toward measurable improvements in delivery performance and business impact.
  • Partner with CCFT leadership to align Agile practices, team priorities, and product execution with strategic business objectives.
  • Drive transformation initiatives that improve how CCFT plans, funds, prioritizes, delivers, measures, and continuously improves product and technology outcomes.
  • Strengthen operational and execution excellence by focusing on Incident Management and Live narratives across product teams within Commercial Tech.
  • Provide direct management, leadership, and mentorship to Scrum Masters and Business Analysts, ensuring their work is aligned to business priorities, team outcomes, and Agile delivery excellence.
  • Shortlist, interview, hire, onboard, and develop Scrum Masters.
  • Mentor Scrum Masters, Release Train Engineers, Product Analysts, and Product Managers to strengthen Agile execution, product thinking, stakeholder alignment, and outcome-based delivery.
  • Establish clear expectations for Agile roles with an emphasis on value delivery, impediment removal, decision enablement, and continuous improvement.
  • Support performance development for Agile delivery roles by connecting individual contributions to team maturity, product outcomes, and organizational goals.
  • Coach global CCFT teams and leaders on applying SAFe, Agile, Lean, and product management practices.
  • Provide practical guidance to teams on Agile events, roles, planning, prioritization, dependency management, and delivery practices.
  • Deliver training, enablement sessions, and workshops for teams, leaders, and stakeholders.
  • Facilitate workshops focused on outcome-based planning, product alignment, Agile governance, continuous improvement, and SAFe adoption.
  • Promote shared learning across teams to scale proven practices and improve Agile capability across CCFT globally.
  • Enable Agile governance practices that improve transparency, accountability, decision-making, and business alignment across CCFT product teams and Agile Release Trains.
  • Establish and promote meaningful Agile and product metrics covering delivery health, predictability, flow, quality, risk, dependencies, customer value, and business impact.
  • Help teams and leaders use metrics to make decisions, identify improvement opportunities, and demonstrate progress against strategic objectives.
  • Conduct regular program reviews with stakeholders to provide visibility into delivery progress, risks, dependencies, value delivered, and outcomes achieved.
  • Ensure Agile measurement practices drive learning, prioritization, and continuous improvement rather than solely administrative reporting.
  • Foster a culture of continuous improvement, innovation, collaboration, accountability, and measurable value delivery across CCFT.
  • Identify systemic delivery impediments and partner with leaders and teams to remove barriers that limit speed, quality, predictability, or business value.
  • Drive improvements in planning, execution, feedback loops, prioritization, dependency management, and stakeholder engagement.
  • Develop reusable accelerators, playbooks, coaching models, and operating practices that improve Agile maturity and business effectiveness.
  • Encourage experimentation and learning to help teams improve delivery outcomes and respond to changing business needs.
  • Act as a change agent by promoting the business value of SAFe, Agile ways of working, DPOM, and product-oriented delivery.
  • Collaborate with leaders, stakeholders, and business partners to build shared understanding of how Agile transformation supports CCFT’s strategic goals and business outcomes.
  • Help teams and stakeholders overcome resistance to change by connecting new ways of working to improved delivery, stronger alignment, and better outcomes.
  • Build partnerships with the Agile Enablement team to scale knowledge sharing, accelerate capability development, and improve organizational Agile maturity.
  • Participate in stakeholder and leadership meetings to communicate transformation progress, business impact, risks, recommendations, and improvement opportunities.
  • Support efficient program execution across CCFT by helping teams improve planning discipline, dependency management, risk management, decision-making, and delivery accountability.
  • Partner with Scrum Masters, Release Train Engineers, Product Analysts, Product Managers, and stakeholders to improve team performance and maintain alignment with business priorities.
  • Help teams understand stakeholder needs, decision-making workflows, business processes, and information requirements to improve delivery relevance and business value.
  • Collaborate with geographically dispersed teams in the United States and international locations to improve consistency, transparency, and delivery outcomes.
  • Ensure Agile delivery practices support product strategy, business objectives, operational excellence, and enterprise priorities.
Desired Qualifications
  • SAFe Practice Consultant certification or equivalent SAFe leadership experience.
  • Experience supporting Agile Release Trains, PI Planning, Inspect and Adapt events, ART execution, and Agile program or portfolio governance.
  • Experience building Agile maturity models, value measurement frameworks, metrics dashboards, coaching playbooks, or transformation accelerators.
  • Experience driving improvements in time-to-market, delivery predictability, quality, stakeholder satisfaction, operational efficiency, or product value realization.
  • Strong communication, facilitation, and stakeholder management skills, with the ability to influence leaders and teams at all levels.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.